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NOX2 Deﬁciency Protects Against Streptozotocin-Induced
-Cell Destruction and Development of Diabetes in Mice
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OBJECTIVE—The role of NOX2-containing NADPH oxidase in
the development of diabetes is not fully understood. We hypoth-
esized that NOX2 deﬁciency decreases reactive oxygen species
(ROS) production and immune response and protects against
streptozotocin (STZ)-induced -cell destruction and develop-
ment of diabetes in mice.
RESEARCH DESIGN AND METHODS—Five groups of
mice—wild-type (WT), NOX2
/, WT treated with apocynin, and
WT adoptively transferred with NOX2
/ or WT splenocytes—
were treated with multiple-low-dose STZ. Blood glucose and
insulin levels were monitored, and an intraperitoneal glucose
tolerance test was performed. Isolated WT and NOX2
/ pancre-
atic islets were treated with cytokines for 48 h.
RESULTS—Signiﬁcantly lower blood glucose levels, higher in-
sulin levels, and better glucose tolerance was observed in
NOX2
/ mice and in WT mice adoptively transferred with
NOX2
/ splenocytes compared with the respective control
groups after STZ treatment. Compared with WT, -cell apoptosis,
as determined by TUNEL staining, and insulitis were signiﬁcantly
decreased, whereas -cell mass was signiﬁcantly increased in
NOX2
/ mice. In response to cytokine stimulation, ROS pro-
duction was signiﬁcantly decreased, and insulin secretion was
preserved in NOX2
/ compared with WT islets. Furthermore,
proinﬂammatory cytokine release induced by concanavalin A
was signiﬁcantly decreased in NOX2
/ compared with WT
splenocytes.
CONCLUSIONS—NOX2 deﬁciency decreases -cell destruction
and preserves islet function in STZ-induced diabetes by reducing
ROS production, immune response, and -cell apoptosis.
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T
ype 1 diabetes is a T-cell–mediated autoimmune
disease characterized by the selective destruc-
tion of insulin-secreting -cells in the islets of
Langerhans. It is a multifactorial process involv-
ing autoantigen presentation by macrophages, dentritic
cells, and B-cells; activation of autoreactive CD4
 T-cells;
and activation and recruitment of -cell–speciﬁc CD8

T-cells, leading to increased cytokine and reactive oxygen
species (ROS) production and destruction of -cells (1).
The mechanisms of putative type 1 diabetes induced by
multiple-low-dose streptozotocin (STZ) includes the direct
-cell destruction, which is mainly induced via DNA
alkylation (2) and the indirect -cell destruction from
T-cell–dependent immune reaction (3). Furthermore, in
response to cytokine stimulation including interleukin
(IL)-1, interferon (IFN)-, and tumor necrosis factor
(TNF)-, -cells also generate ROS and reactive nitrogen
species, which may facilitate their destruction (4). Addi-
tionally, overexpression of antioxidant enzymes including
superoxide dismutase (SOD), catalase, and glutathione
peroxidase 1 (Gpx1) protects against the onset and devel-
opment of diabetes and supports an important role of ROS
in the pathogenesis of immune-mediated diabetes (5–12).
NADPH oxidase is one of the main sources of superoxide
radical formation in many cell types including phagocyte
and -cells (13). This ROS-producing enzyme consists of
two membrane subunits (NOX2 and p22
phox) and at least
four cytosolic components (p40
phox, p47
phox, p67
phox, and
Rac1). NADPH oxidase is a highly regulated enzyme. In
the resting cells, the cytosolic complex is separated from
the membrane-bound catalytic core. Upon stimulation, the
cytosolic component p47
phox becomes phosphorylated
and the cytosolic complex migrates and binds to the
membrane subunits to assemble into an active oxidase
(14). It catalyzes the reduction of oxygen to superoxide
anion using NADPH as a substrate and plays a major
role in antimicrobial host defense as well as in tissue
damage of autoimmune diseases (15,16). NOX2 is one of
the critical subunits of NADPH oxidase. T-cells deﬁcient in
NOX2 exhibit an impaired ability to produce superoxide in
response to anti-CD3 stimulation (17). Furthermore, glu-
cose stimulates -cell superoxide production, which can
be inhibited by a selective NADPH oxidase inhibitor
diphenylene iodonium, suggesting a functional NADPH
oxidase in the islet (18). However, a deﬁnitive role of
NADPH oxidase in the development of diabetes remains to
be determined.
In the present study, NOX2
/ mice were used to
investigate the role of NADPH oxidase in -cell destruc-
tion induced by multiple-low-dose STZ. We demonstrated
that NOX2 deﬁciency attenuates the severity of hypergly-
cemia and the loss of -cell mass induced by STZ treat-
ments via reduced ROS production and suppressed
immune response.
RESEARCH DESIGN AND METHODS
Animals. NOX2
/ and C57BL/6 (wild-type [WT]) mice were obtained from
Jackson Laboratory (Bar Harbor, ME). Male NOX2
/ and WT mice 8–12
weeks old were used in all experiments. Animals in this study were handled
in accordance with the Guide for the Care and Use of Laboratory Animals,
published by the U.S. National Institutes of Health (NIH publ. no. 85-23,
revised 1996).
Adoptive transfer. Single-cell suspensions were prepared from spleens of
NOX2
/ and WT mice as previously described (19). Brieﬂy, spleens were
removed, minced, and ﬁltered through sterile 100-m ﬁlters. Erythrocytes
were lysed, and the nucleated cells were washed resuspended in saline and
injected via the lateral tail vein into irradiated (970 cGy) WT mice (10
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/ and WT splenocytes were termed
WT
NOX2/ and WT
WT, respectively. These mice were allowed to recover for 5
weeks before the induction of diabetes.
Streptozotocin diabetes model. To induce diabetes, WT, NOX2
/,W T
treated with apocynin (10 mg/day/kg body wt i.p.), WT
NOX2/, and WT
WT
mice were treated with STZ (80 mg/kg body wt i.p. for 3 consecutive days).
Additionally, some WT, NOX2
/ mice were treated with saline as vehicle
controls. Random blood glucose levels were monitored on day 2, 5, and 8 after
the ﬁnal injection of STZ with a glucose meter (OneTouch Ultra2; LifeScan
Canada, Burnaby, BC). On day 9, an intraperitoneal glucose tolerance test
(IPGTT) was performed using an intraperitoneal injection of D-glucose at 2
g/kg body wt after 16 h fasting. Blood glucose was analyzed at 0, 15, 30, 60, and
120 min after introducing glucose. Nonfasting serum was collected. Pancreata
were weighed and collected. Diabetic hyperglycemia was deﬁned as a
nonfasting blood glucose concentration 11.1 mmol/l for two or more
consecutive tests.
Alloxan diabetes model. WT, NOX2
/ mice were treated with alloxan (60
mg/kg body wt i.v.). Fasting blood glucose levels were measured, and IPGTT
was performed as described above. Nonfasting serum was collected for
measurement of insulin levels.
Measurement of -cell and islet mass, insulitis, and apoptosis. Pancre-
ata from WT and NOX2
/ mice killed on day 9 were ﬁxed in 4% paraformal-
dehyde for 24 h, embedded in parafﬁn, and serially cut into 5-m sections at
50-m intervals. Immunostaining was performed with an anti-mouse insulin
antibody (1:2,000; Sigma, Oakville, ON) using a mouse-on-mouse immunode-
tection kit (Vector Laboratories, Burlingame, CA). The staining was visualized
using diaminobenzidine. Sections were then counterstained with hematoxylin.
The microscopic images were taken by a Zeiss microscope and analyzed using
AxioVision software. Insulin-positive cells were considered functional -cells.
Relative -cell and islet area to total pancreatic area ratios were calculated.
The -cell and islet mass were then evaluated by multiplying the area ratio
with the pancreatic weight. The evaluation of insulitis score was assigned
using the following scale: 0, intact islet; 1, peri-insulitis; 2, moderate insulitis
(50% of the islet inﬁltrated); and 3, severe insulitis (50% of the islet
inﬁltrated) as previously described (19). For the analysis of pancreatic islet
apoptosis, double staining of in situ cell death detection ﬂuorescein and
insulin ﬂuorescent immunohistochemistry (20) was performed. Pancreata
from WT and NOX2
/ mice killed 8 h after the ﬁnal injection of STZ were
isolated, embedded, and sectioned as described above. Apoptosis and necro-
sis of the islet cells were assessed via hematoxylin staining by the chromatin
morphology (21).
Islet culture and treatment. Pancreatic islets were isolated from NOX2
/
and WT mice by liberase RI (Roche Diagnostics, Laval, QC) digestion as
described previously (22). Isolated pancreatic islets were cultured free-
ﬂoating in RPMI-1640 medium containing 11.1 mmol/l glucose, supplemented
with 2 mmol/l L-glutamine, 10% FCS, 12 mmol/l HEPES, 100 units/ml penicillin,
and 100 g/ml streptomycin in an atmosphere of 95% air and 5% CO2 at 37°C
overnight. Groups of 20 islets were then incubated in 200 l Dulbecco’s
modiﬁed Eagle’s medium containing 11.1 mmol/l glucose supplemented with
2 mmol/l L-glutamine, 10% FCS, 100 units/ml penicillin, and 100 g/ml
streptomycin with or without a cytokine mixture, which consisted of human
recombinant IL-1, IFN-, and TNF- (2 ng/ml each; Sigma) for 48 h at 37°C
in 5% CO2.
Determination of glucose-stimulated insulin release. The insulin secre-
tion assay was performed as previously described (23). Brieﬂy, islets from
each experiment group were incubated in Krebs-Ringer bicarbonate buffer
supplemented with 2 mg/ml BSA and 1.67 mmol/l glucose for 30 min, followed
by a 90-min incubation in Krebs-Ringer bicarbonate HEPES buffer supple-
mented with 2 mg/ml BSA and in the presence of 1.67 or 16.7 mmol/l glucose.
Insulin released during the 90 min was then measured and normalized by the
DNA content of each 20-islet group. DNA content was determined by a
CyQUANT-cell proliferation assay kit (Invitrogen Canada, Burlington, ON).
Detection of total ROS and superoxide production. Total ROS production
in isolated islets was determined by dichloroﬂuorescein diacetate assay.
Islets were homogenized in 100 l buffer solution (50 mmol/l Tris-HCl, pH
7.5, 50 mmol/l KCl, and 10 mmol/l MgCl2) and incubated with 10 mol/l
dichloroﬂuorescein diacetate at 37°C for 3 h. Fluorescence was measured
by excitation (485 nm) and emission (525 nm) spectra with a microplate
reader (SpectraMax M5; Molecular Devices, Sunnyvale, CA). Superoxide
production in serum and isolated islets was determined by dihydro-
ethidium assay. Serum and islets were incubated with 50 mol/l dihydro-
ethidium at 37°C for 30 min. Fluorescence was measured by excitation (396
nm) and emission (579 nm) spectra, which detects 2-hydroxyethidium (a
speciﬁc superoxide-derived dihydroethidium product) (24), using a micro-
plate reader (SpectraMax M5). Superoxide production in splenocytes in
response to concanavalin A (ConA) was measured by lucigenin assay (25).
Brieﬂy, 10
6 splenocytes were treated with ConA (5 g/ml) with or without
FIG. 1. Blood glucose and serum insulin levels after multiple-low-dose
STZ treatment. A and B: NOX2
/ mice and WT mice treated with
apocynin (10 mg/kg body wt/day) showed a signiﬁcant decrease in random
blood glucose levels compared with WT after STZ treatment. C and D:A n
IPGTT 9 days after STZ treatment revealed that glucose clearance was
signiﬁcantly improved in NOX2
/ and in WT mice treated with apocynin,
compared with WT mice. E: NOX2
/mice had a signiﬁcantly lower fasting
blood glucose level than WT mice after STZ treatment. F–H: After STZ
treatment, serum insulin levels (F) in NOX2
/ mice were signiﬁcantly
higher, and superoxide levels (G) were signiﬁcantly lower than those in
WT mice. No difference in blood glucose and serum insulin was found
between control groups. Total antioxidant levels, SOD-2, and Gpx1
expression was similar between WT and NOX2
/ mice (H–J). Data are
means  SEM, n  6–7 per group for A–H, n  4–5 per group for I and J.
*P < 0.05, **P < 0.01 vs. WT control, †P < 0.05 vs. STZ-treated WT. AUC,
area under the curve; RFU, relative ﬂuorescence unit.
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followed by 50 mol/l lucigenin. Luminescence was then measured using a
microplate reader (SpectraMax M5).
Determination of cytokine release from splenocytes. Isolated spleno-
cytes (5 	 10
6) from WT and NOX2
/ mice were cultured overnight and
then incubated with ConA (5 g/ml) for 48 h. TNF- and IL-1 release
in the media was determined by an ELISA kit (eBioscience, San Diego, CA).
Measurement of serum insulin and total antioxidant levels. Culture
media of isolated islets in response to a 90-min stimulation of 1.67 and 16.7
mmol/l glucose were collected. Serum from nonfasting mice was obtained.
Both culture media and serum were stored in 20°C, and their insulin
concentrations were measured by a mouse insulin ELISA kit (ALPCO, Salem,
NH). Serum insulin levels were expressed as micrograms per liter. Insulin
concentrations in the culture media were adjusted by DNA content of the
islets and expressed as nanograms per 100 g islet DNA per 90 min. Serum
total antioxidant levels were detected by a total antioxidant capacity assay kit
(Abcam, Cambridge, MA) and were expressed as milliequivalents per liter of
Trolox per liter (mEq Trolox/l).
Western blot analysis. Antioxidant enzymes manganese SOD (SOD-2) and
Gpx1 protein levels were assessed by Western blotting. Brieﬂy, cell lysates
containing 80 g protein were subjected to sodium dodecyl sulfate–PAGE
using 12% gels, followed by electrotransfer to nitrocellulose membranes.
Blots were probed with antibodies against SOD-2 (1:1,000; Santa Cruz
Biotechnology, Santa Cruz, CA), Gpx1 (1:500; Abcam, MA), and GAPDH
(1:8,000; Santa Cruz Biotechnology) followed by incubation with horserad-
ish peroxidase–conjugated secondary antibodies (1:2,000; Santa Cruz Bio-
technology). Protein bands were detected using the enhanced
chemiluminescence method.
Statistical analysis. Data are presented as means 
 SEM. Statistical analysis
was performed using two-way ANOVA for multiple group comparisons
followed by Bonferroni’s correction or Student t test for comparison between
two groups. Difference in insulitis score between NOX2
/ and WT mice was
analyzed by the 
2 test. A P value of 0.05 was considered statistically
signiﬁcant.
RESULTS
NOX2 deﬁciency decreases STZ-induced hyperglycemia.
Under normal conditions, adult WT and NOX2
/ mice
showed equivalent levels of random blood glucose, serum
superoxide, antioxidant, and insulin (Fig. 1). Two days
after the ﬁnal injection of STZ, ﬁve of seven WT mice
developed hyperglycemia, whereas only one of seven
NOX2
/ mice had blood glucose level 11.1 mmol/l. On
day 5, all WT mice became diabetic, but there were still
two of seven NOX2
/ mice that demonstrated normal
blood glucose levels. Compared with WT mice, NOX2
/
mice presented signiﬁcantly lower random (Fig. 1A and B)
and fasting (Fig. 1E) blood glucose levels after STZ
treatment (P  0.01). Consistently, the results of IPGTT
performed on day 9 as an in vivo measure of -cell
function showed that STZ-induced glucose intolerance
was signiﬁcantly ameliorated in NOX2
/ mice (P  0.01,
Fig. 1C and D). A similar effect was also observed in WT
mice treated with an NADPH oxidase inhibitor, apocynin
(10 mg/kg body wt/day). In concordance to the blood
glucose level results, the serum insulin level was restored
in NOX2
/ mice compared with WT mice (P  0.05, Fig.
1F). Serum superoxide production signiﬁcantly increased
after STZ treatment in both WT and NOX2
/ mice (Fig.
1G). However, compared with WT mice, NOX2
/ mice
presented signiﬁcantly lower serum superoxide levels
(P  0.01, Fig. 1G). No signiﬁcant changes were observed
in serum antioxidant activity levels or protein expression
of antioxidant enzymes including SOD-2 and Gpx1 after
STZ treatment (Fig. 1H–J).
FIG. 2. Islet cell apoptosis after multiple-low-dose STZ treatment. A: Representative histological TUNEL staining of WT and NOX2
/ mouse islets
9 days after STZ treatment. B: STZ-induced -cell apoptosis was signiﬁcantly decreased in NOX2
/ compared with WT mice 9 days after STZ
treatment. C: STZ-induced islet cell apoptosis and necrosis were both signiﬁcantly decreased in NOX2
/ compared with WT mice directly after
STZ treatment for 3 days. Data are means  SEM, n  5–7 per group. **P < 0.01 vs. STZ-treated WT. (A high-quality digital representation of
this ﬁgure is available in the online issue.)
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treatment. Apoptosis is an important mechanism in the
development of diabetes. We examined -cell apoptosis 9
days after STZ treatment by transferase-mediated dUTP
nick-end labeling (TUNEL) staining and co-staining with
insulin. Apoptotic -cells were detected by immunoﬂuo-
rescence associated with fragmented DNA (Fig. 2A). Com-
pared with WT mice, there were signiﬁcantly less TUNEL-
positive -cells in NOX2
/ mouse islets 9 days after STZ
treatment (P  0.01, Fig. 2B). Acute cell death in islets
after STZ treatment was also investigated. Eight hours
after the ﬁnal STZ injection, a signiﬁcant decrease in the
number of apoptotic and necrotic cells in the islets was
observed in NOX2
/ mice compared with WT mice (P 
0.01, Fig. 2C). Furthermore, necrosis was about 15-fold
higher than apoptosis at this early stage of STZ-induced
islet damage (Fig. 2C).
NOX2 deﬁciency preserves -cell mass after STZ
treatment. STZ treatment caused destruction of pancre-
atic -cells (representative histological images of pancre-
atic tissue are shown in Fig. 3A). In WT mice, the number
of functional (insulin immuno-positive) -cells within is-
lets was markedly decreased as a result of STZ treatment.
However, in NOX2
/ mice, -cells appeared to be pro-
tected after the same dose regimen of STZ treatment (Fig.
3A). Compared with controls, -cell mass was signiﬁcantly
decreased in WT mice after STZ treatment (P  0.01).
However, NOX2 deﬁciency signiﬁcantly preserved the
-cell mass (P  0.05, Fig. 3B).
NOX2 deﬁciency attenuated islet insulitis after STZ
treatment. Insulitis is an important process in -cell
destruction induced by STZ. A scoring system was used to
evaluate the extent of insulitis after STZ treatment. An
example of each score grade was shown in Fig. 4A.
Histological analysis showed the presence of insulitis in
both groups of mice, with signiﬁcant differences in the
degree of leukocyte inﬁltration (P  0.01). In NOX2
/
mice, 43% of islets exhibited no insulitis, with 38% of islets
showing only peri-insulitis. However, in WT mice, half of
the islets showed grade 2–3 insulitis (Fig. 4B).
NOX2 deﬁciency improves islet function and de-
creases ROS production during cytokine treatment in
vitro. Islets isolated from WT and NOX2
/ mice showed
a similar level of insulin release in response to glucose
stimulation (Fig. 5A). The cytokine treatment (2 ng/ml
each of IL-1, IFN-, and TNF-) signiﬁcantly decreased
insulin release from the WT islets (P  0.01). However,
this impairment was abrogated in NOX2
/ islets (P 
0.01, Fig. 5A). Cytokine treatment signiﬁcantly increased
FIG. 3. -Cell mass after multiple-low-dose STZ treatment. A: Repre-
sentative histological insulin staining of pancreas sections from each
experiment group. Insulin-positive cells within islets are stained
brown. B: No difference in -cell mass was found between control
groups. After STZ treatment, -cell mass was signiﬁcantly preserved in
NOX2
/ compared with WT mice. Data are means  SEM; n  4–6per
group. **P < 0.01 vs. WT control; †P < 0.05 vs. STZ-treated WT. (A
high-quality digital representation of this ﬁgure is available in the
online issue.)
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FIG. 4. Islet insulitis after multiple-low-dose STZ treatment. A: Repre-
sentative histological images are shown. The insulitis score was as-
signed using the following scale: 0, intact islet (A0); 1, peri-insulitis
(A1); 2, moderate insulitis (A2, <50% of the islet inﬁltrated); 3, severe
insulitis (A3, >50% of the islet inﬁltrated). B: Islets from 10 WT mice
and eight NOX2
/ mice were assigned insulitis scores. Less inﬁltration
was found in NOX2
/ islets compared with WT after STZ treatment
(P < 0.01, 
2 analysis). Data are means  SEM. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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NOX2
/ islets (P  0.01). When compared with WT, both
total ROS (Fig. 5B) and superoxide (Fig. 5C) levels of
NOX2
/ islets were signiﬁcantly decreased (P  0.01).
NOX2 deﬁciency of the immune system decreases
STZ-induced hyperglycemia. Adoptive transfer was
used to replace the WT immune environment with a
NOX2-deﬁcient one. Five weeks after adoptive transfer,
basal blood glucose levels of WT
WT and WT
NOX2/ mice
remained normal. STZ treatment induced a severe hyper-
glycemia in WT
WT mice. However, the WT
NOX2/ mice
demonstrated a signiﬁcantly lower level of random blood
glucose (Fig. 6A and B, P  0.01) and fasting blood glucose
(Fig. 6E, P  0.01), higher serum insulin level (Fig. 6F, P 
0.01), and less intolerance to IPGTT compared with WT
WT
(Fig. 6C and D, P  0.05). WT and NOX2
/ splenocytes
used to perform the adoptive transfer were stimulated
with ConA. Superoxide production detected by lucigenin
assay in response to ConA stimulation was signiﬁcantly
attenuated in NOX2
/ splenocytes compared with WT
(P  0.01, Fig. 6G). Moreover, 48 h after ConA stimulation,
the proinﬂammatory cytokine release (TNF- and IL-1)
was signiﬁcantly impaired in NOX2
/ splenocytes com-
pared with WT (P  0.05, Fig. 6H and I).
NOX2 deﬁciency prevents alloxan-induced diabetes.
After alloxan treatment (60 mg/kg i.v.), all WT mice
developed hyperglycemia, whereas none of the NOX2
/
mice had blood glucose levels 11.1 mmol/l on day 2 and
5. NOX2
/ mice presented signiﬁcantly lower random
(Fig. 7A and B) and fasting (Fig. 7E) blood glucose levels
compared with WT (P  0.01). Consistently, IPGTT per-
formed on day 9 showed that alloxan-induced glucose
intolerance was abrogated in NOX2
/ mice (P  0.01,
Fig. 7C and D). Furthermore, serum insulin levels were
signiﬁcantly increased in NOX2
/ compared with WT
mice after alloxan treatment (P  0.01, Fig. 7F).
DISCUSSION
In the present study, we demonstrated for the ﬁrst time
that deﬁciency of NOX2 protects against the onset and
development of STZ-induced diabetes in mice. STZ-in-
duced hyperglycemia was signiﬁcantly inhibited in
NOX2
/ compared with WT mice. In agreement with the
FIG. 5. Isolated islet function and ROS production after cytokine treatment. A: Glucose-stimulated insulin release after treatment with combined
cytokines for 48 h. Insulin release in response to 16.7 mmol/l glucose was signiﬁcantly impaired in cytokine-treated isolated WT islets compared
with WT control but was well preserved in cytokine-treated NOX2
/ islets. B: Total ROS production detected by dichloroﬂuorescein diacetate
in isolated islets treated with cytokines. After cytokine treatment, ROS in the islets signiﬁcantly increased compared with control groups.
NOX2
/ islets showed a signiﬁcantly lower ROS production compared with WT. C: Superoxide production detected by dihydroethidium in
isolated islets treated with cytokines. After cytokine treatment, superoxide production in the islets was signiﬁcantly increased compared with
control groups. NOX2
/ islets showed a signiﬁcantly lower superoxide production compared with WT. Data are means  SEM; n  4–5 per group.
**P < 0.01 vs. WT control; †P < 0.01 vs. cytokine-treated WT. RFU, relative ﬂuorescence unit.
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IPGTT and the serum insulin levels after STZ treatment
were restored in NOX2
/ mice. Histological investigation
of pancreatic tissue revealed that the majority of -cells in
WT pancreatic islets was destroyed by the STZ, whereas
the -cell mass was well preserved in NOX2
/ mice.
These data clearly showed the protective effects of NOX2
deﬁciency against STZ-induced diabetes, suggesting a crit-
ical role of NOX2-containing NADPH oxidase in -cell
destruction in diabetes.
In the multiple-low-dose STZ model, diabetes is induced
by two main mechanisms (3,26,27). One is the direct
cytotoxic effect of STZ on -cells by alkylation of nuclear
and mitochondrial DNA. The other is the local inﬁltration
in the pancreatic islets and inﬂammation by mononuclear
cells including lymphocytes and macrophages, which sim-
ulate the autoimmune reaction in type 1 diabetes (28).
Although ROS has been implicated in both mechanisms,
the source of the ROS production during development of
diabetes is still not clear. Recently, functional phagocyte-
like NADPH oxidase has been found in T-cells (17) and
-cells (18). NOX has been shown to be quantitatively an
important source of ROS in pancreatic islets (18,29). In the
present study, cell death at 8 h after the third STZ
treatment was signiﬁcantly decreased in the NOX2
/
mice. Although cytokine (IL-1, IFN-, and TNF-) treat-
ment signiﬁcantly increased total ROS and superoxide
production of the WT islets, both total ROS and superox-
ide levels were signiﬁcantly decreased in the NOX2
/
islets. Furthermore, -cell function in terms of insulin
release was well preserved in NOX2
/ islets. Addition-
ally, serum insulin levels and IPGTT were restored in
NOX2
/ mice after STZ treatment in vivo. These data
suggest that NOX2-containing NADPH oxidase plays an
important role not only in the early islet cell death from
STZ, but also cytokine-mediated ROS production in the
islets leading to impairment of -cell function.
Alloxan is another diabetogenic chemical used fre-
quently because of its ability to selectively damage -cells
by inducing ROS formation (3). To further demonstrate
that decreased ROS production due to NOX2 deﬁciency
protects against diabetes, the alloxan diabetes model was
used. Results showed that NOX2 deﬁciency prevented
diabetes development after alloxan treatment. Our data
provide convincing evidence for an important role of
NOX2-mediated ROS production in diabetes development.
Type 1 diabetes is an autoimmune disease. Activation
and recruitment of immune cells including -cell–speciﬁc
CD8
 T-cells have been implicated in the pathogenesis of
diabetes through cytokine expression and ROS production
leading to -cell destruction (1). In fact, recent studies
have shown that T-cells have functional NADPH oxidase
enzyme, and deﬁciency in NOX2 decreases their ability to
produce ROS according to antigen stimulation (17). In the
present study, we isolated splenocytes and measured
ConA-stimulated superoxide production and proinﬂamma-
tory cytokine release, which reﬂects immune cell activa-
tion. Our data showed that superoxide production and
proinﬂammatory cytokine release (TNF- and IL-1) were
signiﬁcantly decreased in NOX2-deﬁcient splenocytes. To
further investigate the contribution of NOX2 in immune
cells to functional impairment and damage of -cells,
NOX2
/ splenocytes were adoptively transferred into
lethally irradiated WT mice to reproduce the altered
immune system in the NOX2 animals. Consistent with our
hypothesis, a signiﬁcantly lower blood glucose level,
higher serum insulin level, and better islet function were
observed in the WT mice repopulated with NOX2 spleno-
cytes compared with the control group after STZ treat-
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FIG. 6. Effects of adoptive transfer with NOX2
/ splenocytes on -cell
function after multiple-low-dose STZ treatment. A–F: Blood glucose
and insulin levels after STZ treatment in mice that underwent adoptive
transfer. WT
NOX2/ and WT
WT indicate WT mice adoptively trans-
ferred with NOX2
/ and WT splenocytes, respectively. The WT
NOX2/
mice showed lower random (A and B) and fasting (E) blood glucose
levels and higher serum insulin level (F) than WT
WT mice after STZ
treatment. IPGTT results (C and D) demonstrated that the in vivo
-cell function of WT
NOX2/ mice was signiﬁcantly preserved when
compared with WT
WT mice after STZ treatment. *P < 0.05, **P < 0.01
vs. WT
WT. G–I: The ability of NOX2
/ splenocytes to produce ROS (G)
and proinﬂammatory cytokines, TNF- (H) and IL-1 (I), in response
to ConA (5 g/ml) simulation was signiﬁcantly impaired compared with
WT splenocytes. *P < 0.05, **P < 0.01 vs. WT. Data are means  SEM;
n  4–6 per group. AUC, area under the curve; RLU, relative lumines-
cence unit.
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oxidase in the activated immune cells including T-cells
also plays a key role in the impairment of islet function
after STZ treatment.
In type 1 diabetes and animal models of STZ-induced
diabetes, leukocytic inﬁltration (insulitis) and the produc-
tion of proinﬂammatory cytokines contribute signiﬁcantly
to -cell destruction (30–32). Inﬁltrated macrophages and
T-cells generate cytotoxic mediators including cytokines
and induce -cell death through apoptosis (33,34). In our
study, decreased insulitis and apoptosis were observed in
the islets of NOX2
/ mice, leading to the well-preserved
-cell mass after STZ treatment, which can be explained
by a reduction of early islet cell death and the decreased
ability of NOX2
/ splenocytes to produce superoxide
and release proinﬂammatory cytokines. Previous studies
have also shown that NOX2 deﬁciency results in decreased
superoxide production from polymorphonuclear neutro-
phils and macrophages (34) and decreased hydrogen per-
oxide generation from T-cells (17). Antigen-presenting
cells deﬁcient in NOX2 have an impaired ability to present
antigens due to enhanced antigen degradation (35). Addi-
tionally, the peripheral blood memory B lymphocyte
compartment is reduced in patients with chronic granulo-
FIG. 7. Blood glucose and serum insulin levels after alloxan treatment. A and B: NOX2
/ mice showed signiﬁcant decreased random blood
glucose levels compared with WT after alloxan treatment. C and D: An IPGTT at 9 days after alloxan treatment revealed that -cell function
was signiﬁcantly better in NOX2
/ mice than in WT mice. E and F: NOX2
/ mice had a signiﬁcantly lower fasting blood glucose level and
higher serum insulin levels than WT mice after alloxan treatment. Data are means  SEM; n  6 per group. **P < 0.01 vs. WT. AUC, area
under the curve.
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ciency (36). Taken together, NOX2 deﬁciency protects
against -cell destruction and preserves islet function in
the STZ-induced diabetes by inhibiting insulitis. These
beneﬁcial effects are likely due to less early -cell death
from toxic effects of STZ and an inhibition of immune
reaction, including decreased antigen presentation, im-
paired immune cell activation, and suppression of cyto-
toxic effects from T-cells, neutrophils, and macrophages
during development of diabetes.
In conclusion, our study demonstrated that NOX2 deﬁ-
ciency attenuates the severity of hyperglycemia, -cell
mass loss, and insulitis in the multiple-low-dose STZ-
induced diabetes in mice. The protective effects are a
result of decreased -cell apoptosis, decreased ROS pro-
duction from the islets, and suppressed immune response.
The ability of NOX2 in regulating the immune response in
this model supports an important role of NOX2-containing
NADPH oxidase in the development of diabetes induced
by STZ. NOX2 may represent a potential therapeutic target
for treatment of diabetes.
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